Immune Design 10-Q 9 Aug 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 03, 2016
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Trading Symbol	IMDZ
Entity Registrant Name	Immune Design Corp.
Entity Central Index Key	1,437,786
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		20,175,578

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 50,531	$ 112,921
Short-term investments	42,058	0
Accounts receivable	377	972
Inventory	724	13
Prepaid expenses	3,534	1,654
Other current assets	79	0
Total current assets	97,303	115,560
Property and equipment, net	488	585
Total assets	97,791	116,145
Current liabilities:
Accounts payable	3,528	3,074
Accrued liabilities	7,113	3,986
Deferred rent, current	23	51
Total current liabilities	10,664	7,111
Other noncurrent liabilities	63	41
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock, $0.001 par value; 100,000,000 shares authorized at June 30, 2016 (unaudited) and December 31, 2015; 20,167,832 and 20,153,202 shares issued and outstanding at June 30, 2016 (unaudited) and December 31, 2015, respectively	20	20
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding	0	0
Additional paid-in capital	243,863	239,181
Accumulated other comprehensive income	30	0
Accumulated deficit	(156,849)	(130,208)
Total stockholders’ equity	87,064	108,993
Total liabilities and stockholders’ equity	$ 97,791	$ 116,145

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Common stock
Par value per share (in USD per share)	$ 0.001	$ 0.001
Shares issued (in shares)	20,167,832	20,153,202
Shares outstanding (in shares)	20,167,832	20,153,202
Shares authorized (in shares)	100,000,000	100,000,000
Preferred stock
Par value per share (in USD per share)	$ 0.001	$ 0.001
Shares issued (in shares)	0	0
Shares outstanding (in shares)	0	0
Shares authorized (in shares)	10,000,000	10,000,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenues:
Product sales	$ 733	$ 19	$ 740	$ 108
Collaborative revenue	400	1,761	2,256	3,610
Total revenues	1,133	1,780	2,996	3,718
Operating expenses:
Cost of product sales	253	44	275	123
Research and development	11,386	8,483	21,956	15,946
General and administrative	3,948	3,778	7,862	7,580
Total operating expenses	15,587	12,305	30,093	23,649
Loss from operations	(14,454)	(10,525)	(27,097)	(19,931)
Interest and other income	107	8	456	8
Net loss	(14,347)	(10,517)	(26,641)	(19,923)
Unrealized gain on investments	10	0	30	0
Comprehensive loss	$ (14,337)	$ (10,517)	$ (26,611)	$ (19,923)
Earnings Per Share
Basic and diluted net loss per share (in USD per share)	$ (0.71)	$ (0.54)	$ (1.32)	$ (1.10)
Weighted Average Number of Shares Outstanding, Diluted
Weighted-average shares used to compute basic and diluted net loss per share (in shares)	20,155,410	19,356,404	20,154,306	18,174,611

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Operating activities
Net loss	$ (26,641)	$ (19,923)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	151	111
Amortization of premium/discount on investments	(28)	0
Stock-based compensation expense	4,581	3,044
Changes in operating assets and liabilities:
Accounts receivable	595	1,091
Inventory	(711)	(409)
Prepaid expenses	(1,880)	201
Accounts payable	454	(4,887)
Accrued liabilities	3,142	(870)
Other	(100)	(16)
Net cash used in operating activities	(20,437)	(21,658)
Investing activities
Purchases of property and equipment	(54)	(206)
Maturities of short-term investments	6,000	0
Purchases of short-term investments	(48,000)	0
Net cash used in investing activities	(42,054)	(206)
Financing activities
Issuance of common stock in public offering, net of offering costs	0	75,359
Proceeds from exercise of stock options and employee stock purchases	101	149
Net cash provided by financing activities	101	75,508
Net (decrease) increase in cash and cash equivalents	(62,390)	53,644
Cash and cash equivalents, beginning of period	112,921	75,354
Cash and cash equivalents, end of period	50,531	128,998
Supplemental cash flow information
Stock option exercises receivable	$ 0	$ 103

Description of the Business

Description of the Business	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of the Business	Description of the Business Immune Design Corp. (we, us or our) is a clinical-stage immunotherapy company focused on cancer with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. We have engineered our technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. We are developing multiple product candidates from our two discovery platforms, ZVex ® and GLAAS™. Our primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are in Phase 1 and Phase 2 clinical trials. In addition, we have licensed to third parties the right to use the GLAAS platform in select infectious disease and allergy indications. We were incorporated in February 2008 in the State of Delaware. Our operations are headquartered in Seattle, Washington, and we have an additional facility in South San Francisco, California.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation and Use of Estimates The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). To conform with GAAP, the preparation of our financial statements requires management to make judgments, assumptions, and estimates that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to, accruals for clinical trial activity, other accrued liabilities, and assumptions used in determining stock-based compensation expenses. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ materially from those estimates. Principles of Consolidation Our condensed consolidated financial statements include the financial position and results of operations of Immune Design Corp. and Immune Design Ltd., our wholly owned subsidiary. Immune Design Ltd. was incorporated in the United Kingdom in February 2016 and to date there have been no financial transactions or balances related to this entity. Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements as of June 30, 2016 and for the three and six months ended June 30, 2016 and 2015 and the related interim information contained within the notes to the condensed consolidated financial statements are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited financial statements and in the opinion of management, reflect all normal recurring adjustments necessary for a fair statement of our financial position for the interim periods presented. The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the results to be expected for the year ended December 31, 2016 or for other future interim periods or years. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2015 included in our Annual Report on Form 10-K for the year ended December 31, 2015 , filed with the Securities and Exchange Commission (SEC) (Annual Report). Short-Term Investments Our short-term investments include funds invested in U.S. Treasury securities with a final maturity of each security of less than one year. All investments are classified as available-for-sale securities and are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses excluded from earnings and reported in other comprehensive income (loss). Purchase premiums and discounts are recognized in interest income using the interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the condensed consolidated statements of operations and comprehensive income (loss) using the specific-identification method. Comprehensive Loss Comprehensive loss is composed of net loss and other comprehensive income or loss that are excluded from net loss. For the periods presented, other comprehensive income consists of unrealized gains on our available-for-sale securities. Revenue Recognition We derive our revenue from collaboration and licensing agreements and the sale of products associated with material transfer, collaboration and supply agreements. Licensing fees are recognized when the amounts are earned and determinable during the applicable period. We recognize up-front nonrefundable license fees when due under contractual agreements and when we do not have a continuing obligation to provide services related to the agreement. Revenue associated with nonrefundable up-front license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue on a straight-line basis over the expected term of our continued involvement in the research and development process. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved, and the milestone payments are due and collectible. If not deemed substantive, we recognize such milestones as revenue on a straight-line basis over the remaining expected term of continued involvement in the research and development process. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable, (2) achievement of the milestone was not reasonably assured at the inception of the arrangement, (3) substantive effort is involved to achieve the milestone, and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with the achievement of the milestone and any ongoing research and development or other services are priced at fair value. Payments received in advance of work performed are recorded as unearned revenue. Certain agreements from which we derive our revenue include multiple deliverables. We recognize the revenue for each deliverable at fair value determined to be the estimated selling price in cases when neither vendor specific objective evidence nor third-party evidence is available. Revenue is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price to the customer is fixed or determinable and (4) collectability is reasonably assured. The evaluation of these revenue recognition criteria requires significant management judgment. For instance, we use judgment to assess collectability based on factors such as the customer’s creditworthiness and past collection history, if applicable. If we determine that collection of a payment is not reasonably assured, revenue recognition is deferred until receipt of payment. We also use judgment to assess whether a price is fixed or determinable including, but not limited to, reviewing contractual terms and conditions related to payment terms. Revenue from product sales of glucopyranosyl lipid A (GLA), a product from our GLAAS platform, is recognized when the risk of loss has passed to the customer or deferred until such time that risk of loss has passed. All revenues associated from the sale of GLA products supplied by us are reported under product sales with the applicable costs reported under cost of product sales. Cost of product sales consist of the direct costs associated with the manufacture and formulation of GLA, including costs to purchase raw materials, third-party contract manufacturing costs, assay testing and ongoing product stability testing. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB), issued Accounting Standards Update (ASU) No. 2014-09, related to the recognition of revenue. ASU 2014-09 requires entities to recognize revenue through the application of a five step model, which includes identification of the contract, identification of the performance obligations, determination of the transaction price, allocation of the transaction price to the performance obligations, and recognition of revenue as the entity satisfies the performance obligations. The FASB has continued to issue ASUs to clarify and provide implementation guidance related to this standard, including ASU No. 2016-08, which clarifies the implementation guidance on principal versus agent considerations, ASU No. 2016-10, which clarifies the identification of performance obligations and the implementation of licensing guidance and ASU No. 2016-12 which provides narrow scope improvements and practical expedients. These standards are effective retrospectively for annual or interim reporting periods beginning after December 15, 2017, with early application permitted for annual reporting periods beginning after December 15, 2016. Early adoption prior to that date is not permitted. We are evaluating the guidance to determine the potential impact on our results of operations, financial condition, cash flows, and financial statement disclosures. In February 2016, FASB issued ASU 2016-02 related to lease accounting. This standard will require organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases that are greater than 12 months in duration. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous GAAP. There continues to be a differentiation between finance leases and operating leases; however, the principal difference from previous guidance is that the lease assets and lease liabilities arising from operating leases will be recognized on the balance sheets. For capital or finance leases, lessees will recognize amortization of the right-of-use asset separately from interest on the lease liability. For operating leases, lessees will recognize a single total lease expense. This standard is effective for public companies for the fiscal years and interim reporting periods beginning after December 15, 2018. We are evaluating the guidance to determine the potential impact on our results of operations, financial condition, cash flows, and financial statement disclosures. In March 2016, FASB issued ASU No. 2016-09 related to stock-based compensation, which primarily changes the accounting for forfeitures and taxes in connection with share-based payment transactions. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, with early adoption permitted. We are evaluating the guidance to determine the potential impact on our results of operations, financial condition, cash flows, and financial statement disclosures.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Because of net losses recognized in each period, potential shares of common stock issuable upon the exercise of outstanding stock options have not been reflected in the calculation of diluted net loss per share due to the anti-dilutive effect. Diluted net loss per share, therefore, does not differ from basic net loss per share. The common stock equivalents issuable upon the exercise of the following dilutive securities have been excluded from the computation of the diluted net loss per share calculation because their effect would have been antidilutive for the periods presented: June 30, 2016 2015 (unaudited) Outstanding options to purchase common stock 3,493,863 2,301,813 Unvested restricted stock units 115,250 — Total outstanding shares of common stock equivalents 3,609,113 2,301,813

Cash Equivalents and Short-Term

Cash Equivalents and Short-Term Investments	6 Months Ended
	Jun. 30, 2016
Investments, Debt and Equity Securities [Abstract]
Cash, Cash Equivalents, and Short-term Investments	Cash Equivalents and Short-Term Investments The amortized cost and fair value of our cash equivalents and short-term investments are as follows (in thousands): June 30, 2016 (unaudited) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Money market funds $ 44,461 $ — $ — $ 44,461 U.S. Treasury securities 42,028 30 — 42,058 Total $ 86,489 $ 30 $ — $ 86,519 Classified as: Cash equivalents $ 44,461 Short-term investments 42,058 Total $ 86,519 All U.S. Treasury securities held as of June 30, 2016 were classified as available-for-sale securities and had contractual maturities of less than one year. There were no realized gains or losses on these securities for the period presented.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments We measure and record cash and cash equivalents and short-term investments at fair value in the accompanying condensed consolidated financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, is as follows: Level 1 : Quoted prices in active markets for identical assets or liabilities. Level 2 : Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 : Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 1 securities consist of highly liquid money market funds and U.S. Treasury securities. The fair value of Level 1 assets has been determined using quoted prices in active markets for identical assets. The following table summarizes our financial assets measured at fair value on a recurring basis (in thousands): June 30, 2016 (unaudited) Assets: LEVEL 1 LEVEL 2 LEVEL 3 TOTAL Money market funds $ 44,461 $ — $ — $ 44,461 U.S. Treasury securities 42,058 — — 42,058 $ 86,519 $ — $ — $ 86,519 December 31, 2015 Assets: LEVEL 1 LEVEL 2 LEVEL 3 TOTAL Money market funds $ 110,657 $ — $ — $ 110,657

Inventory

Inventory	6 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consists of the following (in thousands): June 30, December 31, (unaudited) Work in process $ 719 $ — Finished goods 5 13 Total inventory $ 724 $ 13

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities consist of the following (in thousands): June 30, December 31, (unaudited) Research and development services $ 3,373 $ 2,043 Legal and professional services 122 378 Employee compensation 816 1,538 Unearned revenue 2,802 27 Total accrued liabilities $ 7,113 $ 3,986

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases We lease laboratory and office space under an operating lease in Seattle, Washington. The lease commenced in February 2013 and continues through November 2016, with an option to extend the term for an additional month. We also lease office space under an operating lease in South San Francisco, California. The lease commenced in January 2015 and continues through January 2020, with an option to extend for an additional five years . In connection with this lease, we were required to provide a $121,000 letter of credit as a security deposit. As of June 30, 2016 , no funds had been drawn on the letter of credit. In January 2016, we entered into a lease agreement to lease approximately 20,133 square feet of office and laboratory space in the building located at 1616 Eastlake Ave. E., Seattle, Washington. This lease includes and expands on the space we currently sublease for our headquarters. The term of the lease is five years with one option to extend the lease term by three years . The lease term is expected to commence on January 1, 2017. The annual base rent due under the lease is $1.1 million for the first year and will increase by 2.5% each year thereafter. In connection with this lease agreement, we will be required to provide a $200,000 letter of credit as a security deposit. Contingencies In June 2015, we entered into a clinical supply agreement with NanoPass Technologies LTD (NanoPass) for the use of its intradermal delivery device in certain of our clinical trials. In July 2015, in connection with the execution of the clinical supply agreement, we paid NanoPass an upfront fee of $600,000 for access and rights to use its device. In December 2015, we initiated our Phase 2 clinical trial of CMB305 in patients with soft tissue sarcoma which triggered a milestone payment to NanoPass of $500,000 . Both the upfront fee and milestone payment were capitalized to prepaid expenses on the accompanying condensed consolidated balance sheets and are being amortized to research and development expense over the related milestone periods. As of June 30, 2016 , $222,000 of the payments remain in prepaid expenses and $261,000 and $522,000 have been amortized to research and development expense during the three and six months ended June 30, 2016 , respectively. In addition, we agreed to pay certain future milestone fees up to an aggregate of $4.0 million upon the achievement of certain clinical milestones using the device. Under our license agreements with the Infectious Disease Research Institute (IDRI), we are contingently obligated to pay potential future milestone payments for products developed from our GLAAS platform, which could total up to $2.4 million and $1.3 million , respectively, for the first and each subsequent exclusive licensed product we develop, and $1.3 million and $625,000 , respectively, for the first and each subsequent non-exclusive licensed product we develop. We are contingently obligated to pay potential future milestone payments to third parties as part of certain licensing agreements for the ZVex products we develop, which could total up to $2.0 million in aggregate payments. We also have potential future royalty payments under our licensing agreements as described in Note 9. Payments under these agreements are uncertain due to the occurrence of the events requiring payment under these agreements, including our share of potential future milestone and royalty payments. These payments generally become due and payable only upon achievement of certain clinical development, regulatory or commercial milestones.

License and Collaboration Agree

License and Collaboration Agreements	6 Months Ended
	Jun. 30, 2016
Research and Development [Abstract]
License and Collaboration Agreements	License and Collaboration Agreements Licenses Granted In August 2014, we entered into an agreement with Sanofi under which we granted Sanofi an exclusive license for use of our GLAAS platform to discover, develop and commercialize products to treat peanut allergy. Sanofi may terminate the agreement at any time upon six months' written notice. We recognized no milestone revenue under this agreement for the three and six months ended June 30, 2016 and 2015 . The agreement provides for additional payments of up to $167.0 million based upon the attainment of certain development and commercialization milestones, and tiered royalties on sales of approved products. In October 2010, we entered into three separate license agreements with MedImmune, LLC (MedImmune) pursuant to which we granted MedImmune a worldwide, sublicensable, exclusive license to use GLA to develop and sell vaccines in three different infectious disease indications. Two of the three agreements remain in full force and effect, and the rights granted under the third have returned to us. Under the license agreements, MedImmune is obligated to use commercially reasonable efforts to develop and obtain regulatory approval for a licensed product in certain markets and to market and sell licensed products in any country where it obtains regulatory approval. In 2010, MedImmune paid us upfront payments under the license agreements. Under each license agreement, MedImmune is obligated to make additional payments based on achievement of certain development, regulatory, and commercial milestones for the licensed indication. MedImmune is also obligated to pay us a low double-digit percentage share of non-royalty payments that it receives from sublicensees and a mid single-digit percentage royalty payment on net sales of licensed products, which royalty is subject to reduction under certain circumstances. Under each license agreement, MedImmune is obligated to make additional aggregate payments of up to $62.9 million to $72.5 million , depending on the infectious disease indication, upon the achievement of certain development, regulatory and commercial milestones for the licensed indication. We recognized no revenue under these agreements for the three and six months ended June 30, 2016 and 2015 . Licenses Acquired In July 2008, we licensed certain patent rights, know-how and technology related to our GLAAS platform from IDRI, specifically products and formulations containing GLA and another synthetic TLR4 agonist referred to as SLA. This license was first amended and restated in 2010. In November 2015, we entered into a separate agreement with IDRI to license a patent related to our GLAAS technology in the field of cancer. Under this agreement, we paid IDRI an upfront license fee in the amount of $250,000 , which was recognized as research and development expense. Upon the achievement of certain developmental and regulatory milestones, we will be obligated to pay IDRI up to $250,000 and $125,000 , respectively, for the first and each subsequent licensed product we develop. In December 2015, we entered into a second amended and restated license agreement with IDRI, in which we obtained additional rights under the licensed technology, which rights vary by disease indication, and we returned to IDRI certain previously licensed GLA rights in select, primarily developing-world infectious disease indications. We received an exclusive license for SLA products in oncology, human allergy and addiction, as well as an option to obtain additional exclusive licenses in select infectious disease indications. In December 2015, in connection with the execution of the second amended and restated license agreement, we paid an upfront fee of $2.3 million , which was recorded as research and development expense. We are obligated to pay IDRI up to $2.4 million and $1.3 million , respectively, in additional payments for the first and each subsequent exclusive licensed product we develop, and $1.3 million and $625,000 , respectively, for the first and each subsequent non-exclusive licensed product we develop, based on the achievement of certain developmental and regulatory milestones. In addition, we will be obligated to pay certain commercialization milestones and royalty payments of single-digit percentage of net sales, if and when a licensed product is commercialized. We are also obligated to share with IDRI a percentage of payments received from any third-party sublicensees. Additionally, if we exercise our option for additional infectious disease indications, we will be required to make upfront, milestone and royalty payments for such additional indications, which payments are subject to similar terms and conditions as are applicable to other milestone and royalty payments. We recognized no IDRI license-related milestone fees for the three and six months ended June 30, 2016 and 2015 . In 2009, we licensed certain patent rights utilized in our ZVex development platform from the California Institute of Technology (Caltech). As part of acquiring this license, we issued shares of our common stock to Caltech valued at $25,000 . We make annual minimum royalty payments under the license. In addition, we are obligated to pay Caltech up to an aggregate of $1.6 million upon the achievement of certain development and regulatory milestones and will owe royalty payments on net sales of licensed products in the low single-digit percentage, if and when commercialized. We recognized no Caltech milestone fees for the three and six months ended June 30, 2016 and 2015 . In June 2015, we entered into a clinical supply agreement with NanoPass for the use of their intradermal delivery device in certain of our clinical trials. See Note 8 for additional information. Collaborations In October 2014, we entered into a collaboration with Sanofi Pasteur, the vaccines division of Sanofi, for the development of a Herpes Simplex Virus (HSV) immune therapy. Sanofi Pasteur and Immune Design are each contributing product candidates to the collaboration: Sanofi Pasteur is contributing HSV-529, a clinical-stage replication-defective HSV vaccine product candidate, and we are contributing G103, our preclinical trivalent vaccine product candidate. The collaboration will explore the potential of various combinations of agents, including leveraging our GLAAS platform, with the goal to select the best potential immune therapy for patients. Each company will develop the products jointly through Phase 2 clinical trials, at which point Sanofi Pasteur intends to continue development of the most promising candidate and be responsible for commercialization. Sanofi Pasteur will bear the costs of all preclinical and clinical development, with Immune Design providing a specific formulation of GLA from the GLAAS platform at its cost through Phase 2 studies. Immune Design will be eligible to receive future milestone and royalty payments on any product developed from the collaboration. We recognize funding from collaborative research and development efforts as revenue as we perform or deliver the related services in accordance with contract terms as long as we will receive payment for such services upon standard payment terms. The costs of the related services performed are recorded as research and development expenses on the condensed consolidated statements of operations and comprehensive income (loss). We recognized revenue under this collaboration of $400,000 and $1.8 million for the three months ended June 30, 2016 and 2015 , respectively, and $2.3 million and $3.6 million for the six months ended June 30, 2016 and 2015 , respectively. As of June 30, 2016 , we have $2.8 million in unearned revenue on our accompanying condensed consolidated balance sheets related to this agreement.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Preferred Stock Our board of directors has the authority to fix and determine and to amend the number of shares of any series of preferred stock that is wholly unissued or to be established and to fix and determine and to amend the designation, preferences, voting powers and limitations, and the relative, participating, optional or other rights, of any series of shares of preferred stock that is wholly unissued or to be established. There was no preferred stock issued and outstanding as of June 30, 2016 or December 31, 2015 . Common Stock In April 2015, we closed an underwritten public offering of 3,000,000 shares of our common stock at a price of $26.50 per share. In May 2015, we sold an additional 47,409 shares directly to our underwriters when they exercised a portion of their option to purchase additional shares at $26.50 per share. We received net proceeds of $75.4 million (inclusive of the exercise of a portion of the underwriters' option to purchase additional shares), after underwriting discounts and commissions and offering expenses totaling $5.4 million . We had 20,167,832 and 20,153,202 shares of common stock outstanding as of June 30, 2016 and December 31, 2015 , respectively. Shares of common stock reserved for future issuance were as follows: June 30, December 31, (unaudited) Shares available for issuance under the employee stock purchase plan 507,498 316,322 Options granted and outstanding 3,493,863 2,832,467 Unvested restricted stock units 115,250 — Shares available for future stock option grants 828,229 804,553 Shares of common stock reserved for future issuance 4,944,840 3,953,342 Equity Incentive Plans On January 1, 2016, in accordance with provisions of our 2014 Employee Stock Purchase Plan (2014 ESPP) the authorized shares available under the 2014 ESPP were increased by 200,000 shares. On January 1, 2016, in accordance with provisions of our 2014 Omnibus Incentive Plan (2014 Plan), the authorized shares available under the 2014 Plan were increased by 806,128 shares. There were a total of 2,911,119 shares of common stock authorized under the 2014 Plan as of June 30, 2016 . Employee Stock Purchase Plan During the six months ended June 30, 2016 , 8,824 shares were issued under the 2014 ESPP at a purchase price of $6.94 . Restricted Stock Units In 2016, we began issuing restricted stock units (RSUs) to employees under the 2014 Plan. The fair value of the RSUs is determined on the date of grant based on the market price of our common stock. RSUs are recognized as expense ratably over the vesting period and our RSUs generally vest over four years with 25% of the total award vesting on each anniversary of the vesting commencement date. The activity for our RSUs is summarized as follow: Shares Weighted Average Grant Date Fair Value Outstanding at December 31, 2015 — — Granted 118,000 $ 19.39 Vested — $ — Forfeited (2,750 ) $ 19.39 Outstanding at June 30, 2016 115,250 $ 19.39 Stock Option Activity Summary stock option information is as follows: OPTIONS OUTSTANDING WEIGHTED- AVERAGE EXERCISE PRICE WEIGHTED- AVERAGE REMAINING CONTRACT TERM (in years) AGGREGATE INTRINSIC VALUE (in thousands) Outstanding at December 31, 2015 2,832,467 $ 11.48 8.24 Granted (unaudited) 765,010 $ 17.94 Exercised (unaudited) (5,806 ) $ 6.70 Expired (unaudited) (93,746 ) $ 31.00 Forfeited (unaudited) (4,062 ) $ 20.02 Outstanding at June 30, 2016 (unaudited) 3,493,863 $ 12.65 8.05 $ 8,388 Vested and expected to vest after June 30, 2016 (unaudited) 3,317,424 $ 12.40 7.99 $ 8,311 Exercisable as of June 30, 2016 (unaudited) 1,442,564 $ 7.82 6.74 $ 6,654 As of June 30, 2016 , there was $20.5 million of total unrecognized stock-based compensation expense related to nonvested stock options that is expected to be recognized over a weighted-average period of 2.7 years . The total intrinsic value of options exercised during the six months ended June 30, 2016 and 2015 was $34,000 and $4.4 million , respectively. Stock-Based Compensation Expense Employee stock-based compensation expense recognized was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates. Total stock-based compensation expense recognized in our condensed consolidated statements of operations and comprehensive income (loss) is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 (unaudited) Employee: Research and development $ 927 $ 487 $ 1,936 $ 889 General and administrative 1,258 1,151 2,555 1,945 Non-Employee: Research and development 35 61 37 96 General and administrative 26 114 53 114 Total stock-based compensation expense $ 2,246 $ 1,813 $ 4,581 $ 3,044 We use the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. The fair values of stock options granted to employees were calculated using the following assumptions: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 (unaudited) Weighted-average estimated fair value $8.64 $15.97 $12.48 $21.80 Risk-free interest rate 1.19% - 1.49% 1.56% - 1.72% 1.19% - 1.84% 1.50% - 1.72% Expected term of options (in years) 5.85 - 6.08 6.08 5.50 - 6.08 5.50 - 6.08 Expected stock price volatility 78% - 80% 86% 77% - 80% 82% - 91% Expected dividend yield — — — —

Legal Proceedings

Legal Proceedings	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Legal Proceedings TheraVectys SA v. Immune Design Corp. In October 2013, TheraVectys SA (TVS) a French biotechnology company, filed a complaint against us in the United States District Court for the District of Delaware. TVS alleged that it had entered into a contractual relationship with Henogen SA (Henogen), in 2010 with respect to the production of lentiviral vector vaccines for TVS. Henogen is a contract manufacturing organization with which we contracted for the manufacture of our LV305 product candidate. TVS alleged that its contractual relationship with Henogen contained an exclusivity provision limiting Henogen’s ability to participate in the manufacturing process of a vaccine based on lentiviral DNA vectors for third parties, as well as a provision preventing Henogen from sharing or using certain TVS confidential technology for manufacturing processes developed by TVS with or for the benefit of others. TVS alleged that we entered into a contractual relationship with Henogen in 2012 to manufacture lentiviral vectors for vaccines, which TVS contends interfered with its contract with Henogen and resulted in the use of certain TVS confidential information and trade secrets. The complaint asserted three counts for relief: tortious interference with contractual relationship, unfair competition and misappropriation of trade secrets. TVS did not specify its claimed damages, other than to assert that they exceed $75,000 . TVS also requested in its complaint injunctive relief enjoining us from importing, receiving, possessing or using lentiviral vector vaccines developed or produced by Henogen, but never filed a motion seeking injunctive relief. The parties entered into several stipulations extending the deadline for us to respond to the complaint. On or about April 7, 2014, TVS filed a Notice of Voluntary Dismissal without prejudice of this lawsuit. On or about July 24, 2014, shortly after our Registration Statement on Form S-1 was declared effective by the SEC for our initial public offering, TVS filed a new complaint against us in the Chancery Court of the State of Delaware, alleging facts substantially similar to the prior complaint. In addition, the complaint further alleges that we obtained shipments of lentiviral vectors for vaccines from Henogen and are conducting clinical trials with these lentiviral vectors. The complaint asserts four counts for relief: tortious interference with contractual relationship, unfair competition, misappropriation of trade secrets, and unjust enrichment; claimed damages were not specified. The complaint also requested injunctive relief enjoining us from using lentiviral vectors developed or produced by Henogen, using any other materials or information obtained by Henogen, and citing to the FDA or otherwise relying on any clinical trials using lentiviral vector vaccines developed or produced by Henogen. On or about December 15, 2014, TVS filed a motion for a preliminary injunction seeking, among other things, to enjoin us from making any use of lentiviral vectors pending final resolution of the litigation. A hearing was held on TVS’s motion in January 2015. By order dated March 9, 2015, the Chancery Court denied TVS’ motion for a preliminary injunction. The court has not yet made any final determination on the merits of the lawsuit, which will be determined following a full trial. A trial date has not yet been set. Should TVS wish to continue with the lawsuit, we intend to continue to vigorously defend ourselves. In September 2015, we and TVS participated in a voluntary non-binding mediation. The mediation process did not result in resolution of the claims in the lawsuit. In recent discussions with TVS, the parties are considering entering into a long-term licensing transaction regarding TVS' technology that would provide future benefit to both parties. However, to date we have not reached any agreement with TVS on potential licensing terms or other claims made by TVS. Due to the nature of the litigation and developments to date, there are many material unresolved questions and issues that are critical to achieving agreement on this matter between both parties. It is unclear how the matters will be resolved. As such, we cannot make a reasonable estimate of a potential loss, or range of loss, at this time.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). To conform with GAAP, the preparation of our financial statements requires management to make judgments, assumptions, and estimates that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to, accruals for clinical trial activity, other accrued liabilities, and assumptions used in determining stock-based compensation expenses. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ materially from those estimates.
Principles of Consolidation	Principles of Consolidation Our condensed consolidated financial statements include the financial position and results of operations of Immune Design Corp. and Immune Design Ltd., our wholly owned subsidiary. Immune Design Ltd. was incorporated in the United Kingdom in February 2016 and to date there have been no financial transactions or balances related to this entity.
Short-term Investments	Short-Term Investments Our short-term investments include funds invested in U.S. Treasury securities with a final maturity of each security of less than one year. All investments are classified as available-for-sale securities and are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses excluded from earnings and reported in other comprehensive income (loss). Purchase premiums and discounts are recognized in interest income using the interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the condensed consolidated statements of operations and comprehensive income (loss) using the specific-identification method.
Comprehensive Income (Loss)	Comprehensive Loss Comprehensive loss is composed of net loss and other comprehensive income or loss that are excluded from net loss. For the periods presented, other comprehensive income consists of unrealized gains on our available-for-sale securities.
Revenue Recognition	Revenue Recognition We derive our revenue from collaboration and licensing agreements and the sale of products associated with material transfer, collaboration and supply agreements. Licensing fees are recognized when the amounts are earned and determinable during the applicable period. We recognize up-front nonrefundable license fees when due under contractual agreements and when we do not have a continuing obligation to provide services related to the agreement. Revenue associated with nonrefundable up-front license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue on a straight-line basis over the expected term of our continued involvement in the research and development process. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved, and the milestone payments are due and collectible. If not deemed substantive, we recognize such milestones as revenue on a straight-line basis over the remaining expected term of continued involvement in the research and development process. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable, (2) achievement of the milestone was not reasonably assured at the inception of the arrangement, (3) substantive effort is involved to achieve the milestone, and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with the achievement of the milestone and any ongoing research and development or other services are priced at fair value. Payments received in advance of work performed are recorded as unearned revenue. Certain agreements from which we derive our revenue include multiple deliverables. We recognize the revenue for each deliverable at fair value determined to be the estimated selling price in cases when neither vendor specific objective evidence nor third-party evidence is available. Revenue is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price to the customer is fixed or determinable and (4) collectability is reasonably assured. The evaluation of these revenue recognition criteria requires significant management judgment. For instance, we use judgment to assess collectability based on factors such as the customer’s creditworthiness and past collection history, if applicable. If we determine that collection of a payment is not reasonably assured, revenue recognition is deferred until receipt of payment. We also use judgment to assess whether a price is fixed or determinable including, but not limited to, reviewing contractual terms and conditions related to payment terms. Revenue from product sales of glucopyranosyl lipid A (GLA), a product from our GLAAS platform, is recognized when the risk of loss has passed to the customer or deferred until such time that risk of loss has passed. All revenues associated from the sale of GLA products supplied by us are reported under product sales with the applicable costs reported under cost of product sales. Cost of product sales consist of the direct costs associated with the manufacture and formulation of GLA, including costs to purchase raw materials, third-party contract manufacturing costs, assay testing and ongoing product stability testing.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB), issued Accounting Standards Update (ASU) No. 2014-09, related to the recognition of revenue. ASU 2014-09 requires entities to recognize revenue through the application of a five step model, which includes identification of the contract, identification of the performance obligations, determination of the transaction price, allocation of the transaction price to the performance obligations, and recognition of revenue as the entity satisfies the performance obligations. The FASB has continued to issue ASUs to clarify and provide implementation guidance related to this standard, including ASU No. 2016-08, which clarifies the implementation guidance on principal versus agent considerations, ASU No. 2016-10, which clarifies the identification of performance obligations and the implementation of licensing guidance and ASU No. 2016-12 which provides narrow scope improvements and practical expedients. These standards are effective retrospectively for annual or interim reporting periods beginning after December 15, 2017, with early application permitted for annual reporting periods beginning after December 15, 2016. Early adoption prior to that date is not permitted. We are evaluating the guidance to determine the potential impact on our results of operations, financial condition, cash flows, and financial statement disclosures. In February 2016, FASB issued ASU 2016-02 related to lease accounting. This standard will require organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases that are greater than 12 months in duration. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous GAAP. There continues to be a differentiation between finance leases and operating leases; however, the principal difference from previous guidance is that the lease assets and lease liabilities arising from operating leases will be recognized on the balance sheets. For capital or finance leases, lessees will recognize amortization of the right-of-use asset separately from interest on the lease liability. For operating leases, lessees will recognize a single total lease expense. This standard is effective for public companies for the fiscal years and interim reporting periods beginning after December 15, 2018. We are evaluating the guidance to determine the potential impact on our results of operations, financial condition, cash flows, and financial statement disclosures. In March 2016, FASB issued ASU No. 2016-09 related to stock-based compensation, which primarily changes the accounting for forfeitures and taxes in connection with share-based payment transactions. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, with early adoption permitted. We are evaluating the guidance to determine the potential impact on our results of operations, financial condition, cash flows, and financial statement disclosures.
Net Loss Per Share	Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Because of net losses recognized in each period, potential shares of common stock issuable upon the exercise of outstanding stock options have not been reflected in the calculation of diluted net loss per share due to the anti-dilutive effect. Diluted net loss per share, therefore, does not differ from basic net loss per share.
Fair Value Measurement	We measure and record cash and cash equivalents and short-term investments at fair value in the accompanying condensed consolidated financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, is as follows: Level 1 : Quoted prices in active markets for identical assets or liabilities. Level 2 : Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 : Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 1 securities consist of highly liquid money market funds and U.S. Treasury securities. The fair value of Level 1 assets has been determined using quoted prices in active markets for identical assets.

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Common Stock Issuable Upon the Conversion or Exercise of Dilutive Securities Excluded from Diluted Net Loss Per Share Attributable to Common Stockholders	The common stock equivalents issuable upon the exercise of the following dilutive securities have been excluded from the computation of the diluted net loss per share calculation because their effect would have been antidilutive for the periods presented: June 30, 2016 2015 (unaudited) Outstanding options to purchase common stock 3,493,863 2,301,813 Unvested restricted stock units 115,250 — Total outstanding shares of common stock equivalents 3,609,113 2,301,813

Cash Equivalents and Short-Te19

Cash Equivalents and Short-Term Investments (Tables)	6 Months Ended
	Jun. 30, 2016
Investments, Debt and Equity Securities [Abstract]
Cash and Cash Equivalents and Short-term Investments	The amortized cost and fair value of our cash equivalents and short-term investments are as follows (in thousands): June 30, 2016 (unaudited) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Money market funds $ 44,461 $ — $ — $ 44,461 U.S. Treasury securities 42,028 30 — 42,058 Total $ 86,489 $ 30 $ — $ 86,519 Classified as: Cash equivalents $ 44,461 Short-term investments 42,058 Total $ 86,519

Fair Value of Financial Instr20

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Financial Assets Measured at Fair Value on a Recurring Basis	The following table summarizes our financial assets measured at fair value on a recurring basis (in thousands): June 30, 2016 (unaudited) Assets: LEVEL 1 LEVEL 2 LEVEL 3 TOTAL Money market funds $ 44,461 $ — $ — $ 44,461 U.S. Treasury securities 42,058 — — 42,058 $ 86,519 $ — $ — $ 86,519 December 31, 2015 Assets: LEVEL 1 LEVEL 2 LEVEL 3 TOTAL Money market funds $ 110,657 $ — $ — $ 110,657

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
Inventory	Inventory consists of the following (in thousands): June 30, December 31, (unaudited) Work in process $ 719 $ — Finished goods 5 13 Total inventory $ 724 $ 13

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): June 30, December 31, (unaudited) Research and development services $ 3,373 $ 2,043 Legal and professional services 122 378 Employee compensation 816 1,538 Unearned revenue 2,802 27 Total accrued liabilities $ 7,113 $ 3,986

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Schedule of Shares of Common Stock Reserved for Future Issuance	Shares of common stock reserved for future issuance were as follows: June 30, December 31, (unaudited) Shares available for issuance under the employee stock purchase plan 507,498 316,322 Options granted and outstanding 3,493,863 2,832,467 Unvested restricted stock units 115,250 — Shares available for future stock option grants 828,229 804,553 Shares of common stock reserved for future issuance 4,944,840 3,953,342
Schedule of Restricted Stock Unit Activity	The activity for our RSUs is summarized as follow: Shares Weighted Average Grant Date Fair Value Outstanding at December 31, 2015 — — Granted 118,000 $ 19.39 Vested — $ — Forfeited (2,750 ) $ 19.39 Outstanding at June 30, 2016 115,250 $ 19.39
Summary of Stock Options	Summary stock option information is as follows: OPTIONS OUTSTANDING WEIGHTED- AVERAGE EXERCISE PRICE WEIGHTED- AVERAGE REMAINING CONTRACT TERM (in years) AGGREGATE INTRINSIC VALUE (in thousands) Outstanding at December 31, 2015 2,832,467 $ 11.48 8.24 Granted (unaudited) 765,010 $ 17.94 Exercised (unaudited) (5,806 ) $ 6.70 Expired (unaudited) (93,746 ) $ 31.00 Forfeited (unaudited) (4,062 ) $ 20.02 Outstanding at June 30, 2016 (unaudited) 3,493,863 $ 12.65 8.05 $ 8,388 Vested and expected to vest after June 30, 2016 (unaudited) 3,317,424 $ 12.40 7.99 $ 8,311 Exercisable as of June 30, 2016 (unaudited) 1,442,564 $ 7.82 6.74 $ 6,654
Schedule of Stock-Based Compensation Expense Recognized	Total stock-based compensation expense recognized in our condensed consolidated statements of operations and comprehensive income (loss) is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 (unaudited) Employee: Research and development $ 927 $ 487 $ 1,936 $ 889 General and administrative 1,258 1,151 2,555 1,945 Non-Employee: Research and development 35 61 37 96 General and administrative 26 114 53 114 Total stock-based compensation expense $ 2,246 $ 1,813 $ 4,581 $ 3,044
Schedule of Fair Value of Stock Options Granted to Employees	The fair values of stock options granted to employees were calculated using the following assumptions: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 (unaudited) Weighted-average estimated fair value $8.64 $15.97 $12.48 $21.80 Risk-free interest rate 1.19% - 1.49% 1.56% - 1.72% 1.19% - 1.84% 1.50% - 1.72% Expected term of options (in years) 5.85 - 6.08 6.08 5.50 - 6.08 5.50 - 6.08 Expected stock price volatility 78% - 80% 86% 77% - 80% 82% - 91% Expected dividend yield — — — —

Description of the Business - N

Description of the Business - Narrative (Details)	6 Months Ended
	Jun. 30, 2016platform
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of discovery platforms	2

Net Loss Per Share - Common Sto

Net Loss Per Share - Common Stock Issuable Upon the Conversion or Exercise of Dilutive Securities Excluded from Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	3,609,113	2,301,813
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	3,493,863	2,301,813
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	115,250	0

Cash Equivalents and Short-Te26

Cash Equivalents and Short-Term Investments (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Gain (Loss) on Investments [Line Items]
Money market funds, amortized cost	$ 44,461
Money market funds, fair value	44,461
Gross unrealized gains	30
Gross unrealized losses	0
Cash equivalents and short-term investments, amortized cost	86,489
Cash equivalents and short-term investments, fair value	86,519
Cash equivalents, fair value	44,461
Short-term Investments, fair value	42,058
Cash equivalents and short-term investments, fair value	86,519
US Treasury Securities [Member]
Gain (Loss) on Investments [Line Items]
Amortized cost basis	42,028
Gross unrealized gains	30
Gross unrealized losses	0
Fair value	$ 42,058

Fair Value of Financial Instr27

Fair Value of Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	$ 44,461
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	44,461	$ 110,657
U.s. Treasury securities	42,058
Investments, fair value	86,519
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	44,461	110,657
U.s. Treasury securities	42,058
Investments, fair value	86,519
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	0	0
U.s. Treasury securities	0
Investments, fair value	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	0	$ 0
U.s. Treasury securities	0
Investments, fair value	$ 0

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Work in process	$ 719	$ 0
Finished goods	5	13
Total inventory	$ 724	$ 13

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Research and development services	$ 3,373	$ 2,043
Legal and professional services	122	378
Employee compensation	816	1,538
Unearned revenue	2,802	27
Total accrued liabilities	$ 7,113	$ 3,986

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details)	1 Months Ended				3 Months Ended		6 Months Ended
	Jan. 31, 2016USD ($)ft²	Dec. 31, 2015USD ($)	Jul. 31, 2015USD ($)	Jan. 31, 2015USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)
Other Commitments [Line Items]
Lessee Leasing Arrangements, Operating Leases, Area of Lease | ft²	20,133
Lessee Leasing Arrangements, Operating Leases, Term of Contract	5 years
Optional lease extension period	3 years			5 years
Operating Leases, Rent Expense, Minimum Rentals	$ 1,100,000
Operating Leases, Rent Expense, Minimum Rentals, Annual Increase	2.50%
Funds drawn on letter of credit					$ 0		$ 0
Prepaid expenses		$ 1,654,000			3,534,000		3,534,000
Research and development					11,386,000	$ 8,483,000	21,956,000	$ 15,946,000
Collaborative Arrangement [Member] | ZVex Product [Member] | Maximum [Member]
Other Commitments [Line Items]
Potential future milestone payments					2,000,000		2,000,000
NanoPass Technologies LTD [Member] | Collaborative Arrangement [Member] | Intradermal Delivery Device [Member]
Other Commitments [Line Items]
Collaborative Arrangement, License Fee		$ 500,000	$ 600,000
Prepaid expenses					222,000		222,000
Research and development					261,000		522,000
NanoPass Technologies LTD [Member] | Collaborative Arrangement [Member] | Intradermal Delivery Device [Member] | Maximum [Member]
Other Commitments [Line Items]
Potential future milestone payments					4,000,000		4,000,000
Infectious Disease Research Institute [Member] | Collaborative Arrangement [Member] | GLA/SLA First Exclusive Product [Member] | Maximum [Member]
Other Commitments [Line Items]
Potential future milestone payments					2,400,000		2,400,000
Infectious Disease Research Institute [Member] | Collaborative Arrangement [Member] | GLA/SLA Subsequent Exclusive Products [Member] | Maximum [Member]
Other Commitments [Line Items]
Potential future milestone payments					1,300,000		1,300,000
Infectious Disease Research Institute [Member] | Collaborative Arrangement [Member] | GLA/SLA First Non-Exclusive Product [Member] | Maximum [Member]
Other Commitments [Line Items]
Potential future milestone payments					1,300,000		1,300,000
Infectious Disease Research Institute [Member] | Collaborative Arrangement [Member] | GLA/SLA Subsequent Non-Exclusive Products [Member] | Maximum [Member]
Other Commitments [Line Items]
Potential future milestone payments					$ 625,000		$ 625,000
Financial Standby Letter of Credit [Member]
Other Commitments [Line Items]
Letter of credit provided as security deposit	$ 200,000			$ 121,000

License and Collaboration Agr31

License and Collaboration Agreements - Narrative (Details)	1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2015USD ($)	Nov. 30, 2015USD ($)	Jun. 30, 2016USD ($)license_agreement	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)license_agreement	Jun. 30, 2015USD ($)	Dec. 31, 2009USD ($)	Oct. 31, 2010license_agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development			$ 11,386,000	$ 8,483,000	$ 21,956,000	$ 15,946,000
GLAAS Discovery Platform [Member] | Collaborative Arrangement, Product [Member] | Sanofi [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized			0	0	0	0
GLAAS Discovery Platform [Member] | Collaborative Arrangement, Product [Member] | Sanofi [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone receivables			167,000,000		167,000,000
GLAAS Discovery Platform [Member] | Collaborative Arrangement [Member] | Infectious Disease Research Institute [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development		$ 250,000
GLA [Member] | Collaborative Arrangement, Product [Member] | MedImmune LLC [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized			$ 0	0	$ 0	0
Number of license agreements | license_agreement								3
Number of license agreements in full force and effect | license_agreement			2		2
GLA [Member] | Collaborative Arrangement, Product [Member] | MedImmune LLC [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone receivables			$ 72,500,000		$ 72,500,000
GLA [Member] | Collaborative Arrangement, Product [Member] | MedImmune LLC [Member] | Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone receivables			62,900,000		62,900,000
GLA [Member] | Collaborative Arrangement [Member] | Infectious Disease Research Institute [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development			0	0	0	0
First GLAAS Discovery Platform Product [Member] | Collaborative Arrangement [Member] | Infectious Disease Research Institute [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments			250,000		250,000
Subsequent GLAAS Discovery Platform Products [Member] | Collaborative Arrangement [Member] | Infectious Disease Research Institute [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments			125,000		125,000
GLA/SLA Product [Member] | Collaborative Arrangement [Member] | Infectious Disease Research Institute [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development	$ 2,300,000
GLA/SLA First Exclusive Product [Member] | Collaborative Arrangement [Member] | Infectious Disease Research Institute [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments			2,400,000		2,400,000
GLA/SLA Subsequent Exclusive Products [Member] | Collaborative Arrangement [Member] | Infectious Disease Research Institute [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments			1,300,000		1,300,000
GLA/SLA First Non-Exclusive Product [Member] | Collaborative Arrangement [Member] | Infectious Disease Research Institute [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments			1,300,000		1,300,000
GLA/SLA Subsequent Non-Exclusive Products [Member] | Collaborative Arrangement [Member] | Infectious Disease Research Institute [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments			625,000		625,000
Dendritic Cell-targeted Theraputic and Prophylactic Immunization Strategies [Member] | Collaborative Arrangement [Member] | California Institute of Technology [Member] | Common Stock [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Value of common stock issued for license							$ 25,000
Dendritic Cell-targeted Theraputic and Prophylactic Immunization Strategies [Member] | Collaborative Arrangement [Member] | California Institute of Technology [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments			1,600,000		1,600,000
Herpes Simplex Virus Immune Therapy [Member] | Collaborative Arrangement, Product [Member] | Sanofi Pasteur [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred Revenue			2,800,000		2,800,000
Herpes Simplex Virus Immune Therapy [Member] | Collaborative Arrangement, Product [Member] | Sanofi Pasteur [Member] | Collaboration Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized			$ 400,000	$ 1,800,000	$ 2,300,000	$ 3,600,000

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 01, 2016	May 31, 2015	Apr. 30, 2015	May 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock in public offering, net of offering costs					$ 0	$ 75,359
Offering costs				$ 5,400
Shares outstanding (in shares)					20,167,832		20,153,202
Intrinsic value of stock options exercised					$ 34	$ 4,400
2014 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in authorized shares	806,128
Common stock authorized (in shares)					2,911,119
Employee Stock [Member] | 2014 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)					$ 6.94
Increase in authorized shares	200,000
Shares issued for employee stock purchase plan (in shares)					8,824
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period					4 years
Annual vesting percent					25.00%
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock based compensation expense					$ 20,500
Weighted average recognition period for stock-based compensation expense					2 years 8 months 12 days
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share issued during period		47,409	3,000,000
Share price (in dollars per share)		$ 26.50	$ 26.50	$ 26.50
Issuance of common stock in public offering, net of offering costs				$ 75,400

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Details) - shares	Jun. 30, 2016	Dec. 31, 2015
Class of Stock [Line Items]
Common stock reserved for future issuance (in shares)	4,944,840	3,953,342
Employee Stock [Member]
Class of Stock [Line Items]
Common stock reserved for future issuance (in shares)	507,498	316,322
Stock Options Outstanding [Member]
Class of Stock [Line Items]
Common stock reserved for future issuance (in shares)	3,493,863	2,832,467
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Common stock reserved for future issuance (in shares)	115,250	0
Future Stock Grants [Member]
Class of Stock [Line Items]
Common stock reserved for future issuance (in shares)	828,229	804,553

Stockholders' Equity - Schedu34

Stockholders' Equity - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding at December 31, 2015 (in shares) | shares	0
Granted (in shares) | shares	118,000
Vested (in shares) | shares	0
Forfeited (in shares) | shares	(2,750)
Outstanding at June 30, 2016 (in shares) | shares	115,250
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Outstanding at December 31, 2015 (in dollars per share) | $ / shares	$ 0
Granted (in dollars per share) | $ / shares	19.39
Vested (in dollars per share) | $ / shares	0
Forfeited (in dollars per share) | $ / shares	19.39
Outstanding at June 30, 2016 (in dollars per share) | $ / shares	$ 19.39

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options outstanding, Beginning balance (in shares)	2,832,467
Options granted in period (in shares)	765,010
Options exercised in period (in shares)	(5,806)
Options expired in period (in shares)	(93,746)
Options forfeited in period (in shares)	(4,062)
Options outstanding, Ending balance (in shares)	3,493,863	2,832,467
Options vested and expected to vest after June 30, 2016 (in shares)	3,317,424
Exercisable options as of June 30, 2016 (in shares)	1,442,564
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price, Beginning balance (in USD per share)	$ 11.48
Weighted average exercise price of options granted in period (in USD per share)	17.94
Weighted average exercise price of options exercised in period (in USD per share)	6.70
Weighted average exercise price of options expired in period (in USD per share)	31
Weighted average exercise price of options forfeited in period (in USD per share)	20.02
Weighted average exercise price, Ending balance (in USD per share)	12.65	$ 11.48
Weighted average exercise price of options vested and expected to vest after June 30, 2016 (in USD per share)	12.40
Weighted average exercise price of exercisable options as of June 30, 2016 (in USD per share)	$ 7.82
Weighted average remaining contract term for outstanding options	8 years 18 days	8 years 2 months 26 days
Weighted average remaining contract term for options vested and expected to vest after June 30, 2016	7 years 11 months 26 days
Weighted average remaining contract term for exercisable options as of June 30, 2016	6 years 8 months 26 days
Aggregate intrinsic value	$ 8,388
Aggregate intrinsic value of options vested and expected to vest after June 30, 2016	8,311
Aggregate intrinsic value of exercisable options as of June 30, 2016	$ 6,654

Stockholders' Equity - Schedu36

Stockholders' Equity - Schedule of Stock-Based Compensation Expense Recognized (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 2,246	$ 1,813	$ 4,581	$ 3,044
Employee [Member] | Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	927	487	1,936	889
Employee [Member] | General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	1,258	1,151	2,555	1,945
Non-Employee [Member] | Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	35	61	37	96
Non-Employee [Member] | General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 26	$ 114	$ 53	$ 114

Stockholders' Equity - Schedu37

Stockholders' Equity - Schedule of Fair Value of Stock Options Granted to Employees (Details) - Employee Stock Option [Member] - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average estimated fair value	$ 8.64	$ 15.97	$ 12.48	$ 21.80
Risk-free interest rate min	1.19%	1.56%	1.19%	1.50%
Risk-free interest rate max	1.49%	1.72%	1.84%	1.72%
Expected stock price volatility minimum	78.00%	86.00%	77.00%	82.00%
Expected stock price volatility maximum	80.00%	86.00%	80.00%	91.00%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time to maturity	5 years 10 months 6 days	6 years 29 days	5 years 6 months	5 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time to maturity	6 years 29 days	6 years 29 days	6 years 29 days	6 years 29 days

Legal Proceedings (Details)

Legal Proceedings (Details) - TheraVectys SA v. Immune Design Corp. [Member]	Jul. 24, 2014count	Oct. 31, 2013USD ($)
Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of counts for relief | count	4
Minimum [Member] | Voluntarily Dismissed Litigation [Member]
Loss Contingencies [Line Items]
Claimed damages, more than | $		$ 75,000